Terminated PHASE2 INTERVENTIONAL 2-arm NCT01374789

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PURO)

PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS

Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Conditions Urinary Bladder Cancer

Interventions GemCis GemCis + Panitumumab

Updated 7 times since 2017 Last updated: Jun 2, 2015 Started: Jul 31, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to insufficient recruitment.

Other terminated trials from Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Ovarian Cancer · Phase PHASE2 · Jan 2019

More terminations from Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

This PHASE2 trial investigates Urinary Bladder Cancer and is currently terminated or withdrawn. Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Sep 2020 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Jun 2018 — Sep 2020 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
WiSP Wissenschaftlicher Service Pharma GmbH

Data source: WiSP Wissenschaftlicher Service Pharma GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Cologne, Germany , Dortmund, Germany , Dresden, Germany , Düsseldorf, Germany , Erlangen, Germany , Fulda, Germany , Hamburg, Germany , Hanover, Germany , Heidelberg, Germany and 9 more locations